ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Citigroup DBN MB

Citigroup DBN MB (CTGP34)

80.69
-1.54
(-1.87%)
마감 23 1월 5:55AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
80.38
매수가
80.38
매도가
0.00
거래량
3,157
80.41 일간 변동폭 81.76
42.48 52주 범위 86.41
market_cap
전일 종가
82.23
개장가
81.50
최근 거래 시간
1
@
80.38
마지막 거래 시간
재정 규모
R$ 255,666
VWAP
80.984
평균 볼륨(3m)
15,567
발행 주식
29,179,491
배당수익률
1.97%
주가수익률
0.30
주당순이익(EPS)
275.19
매출
78.79B
순이익
8.03B

Citigroup DBN MB 정보

섹터
National Commercial Banks - Non Islamic
산업
National Commercial Banks - Non Islamic
웹사이트
본부
New York, New York, USA
설립됨
-
Citigroup DBN MB is listed in the National Commercial Banks - Non Islamic sector of the 브라질 보베스파 거래소 with ticker CTGP34. The last closing price for Citigroup DBN MB was R$82.23. Over the last year, Citigroup DBN MB shares have traded in a share price range of R$ 42.48 to R$ 86.41.

Citigroup DBN MB currently has 29,179,491 shares in issue. The market capitalisation of Citigroup DBN MB is R$2.40 billion. Citigroup DBN MB has a price to earnings ratio (PE ratio) of 0.30.

CTGP34 최신 뉴스

No news to show yet.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
14.736.252478519575.6586.4173.42368280.13539274DR
47.8210.777287761972.5686.4171.351242777.57849158DR
1218.2329.332260659762.1586.4160.111556770.31781998DR
2619.732.465392221560.6886.4151.421344664.91587737DR
5237.788.331771321542.6886.4142.481334858.61417604DR
15623.3841.01754385965786.4131.841131647.76156911DR
260-257.57-76.2154164817337.95347.1731.84865355.02845138DR

CTGP34 - Frequently Asked Questions (FAQ)

What is the current Citigroup DBN MB share price?
The current share price of Citigroup DBN MB is R$ 80.38
How many Citigroup DBN MB shares are in issue?
Citigroup DBN MB has 29,179,491 shares in issue
What is the market cap of Citigroup DBN MB?
The market capitalisation of Citigroup DBN MB is BRL 2.4B
What is the 1 year trading range for Citigroup DBN MB share price?
Citigroup DBN MB has traded in the range of R$ 42.48 to R$ 86.41 during the past year
What is the PE ratio of Citigroup DBN MB?
The price to earnings ratio of Citigroup DBN MB is 0.3
What is the cash to sales ratio of Citigroup DBN MB?
The cash to sales ratio of Citigroup DBN MB is 0.03
What is the reporting currency for Citigroup DBN MB?
Citigroup DBN MB reports financial results in USD
What is the latest annual turnover for Citigroup DBN MB?
The latest annual turnover of Citigroup DBN MB is USD 78.79B
What is the latest annual profit for Citigroup DBN MB?
The latest annual profit of Citigroup DBN MB is USD 8.03B
What is the registered address of Citigroup DBN MB?
The registered address for Citigroup DBN MB is 388 GREENWICH STREET, NEW YORK, NEW YORK, 10013
What is the Citigroup DBN MB website address?
The website address for Citigroup DBN MB is www.citigroup.com
Which industry sector does Citigroup DBN MB operate in?
Citigroup DBN MB operates in the NATIONAL COMMERCIAL BANKS - NON ISLAMIC sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ZAMP3Zamp S.A.
R$ 2.94
(14.40%)
992.1k
OPCT3Oceanpact Servicos Maritimos S.A
R$ 5.59
(12.93%)
4.56M
AZEV11Azevedo Travassos Sa
R$ 0.29
(11.54%)
28.7k
ONCO3Oncoclinicas Brasil Servicos Medico
R$ 2.22
(8.82%)
11.99M
AZUL4AZUL SA
R$ 4.60
(6.98%)
24.08M
AMAR11Lojas Marisa S.A.
R$ 0.47
(-14.55%)
3.2k
BSLI4Banco De Brasilia SA
R$ 7.20
(-9.32%)
600
PGMN11Empreendimentos Pague Menos S.A.
R$ 0.51
(-8.93%)
14.5k
RCSL3Recrusul Sa
R$ 4.20
(-8.89%)
4.66M
OIBR4Oi
R$ 8.61
(-8.60%)
86.3k
HAPV3Hapvida Participacoes Investimento SA
R$ 2.31
(1.32%)
55.24M
ABEV3Ambev SA
R$ 11.02
(-2.04%)
44.99M
BBDC4Bco Bradesco Sa
R$ 11.48
(-1.37%)
42.53M
VALE3Vale SA
R$ 52.66
(-2.52%)
34.65M
CVCB3CVC Brasil Operadora E Agencia De Viagens SA
R$ 1.84
(6.36%)
32.57M
lovethatgreen lovethatgreen 6 분 전
I don't think there is a group anymore it's just him and he's broke
SINC
Shawonsarker84 Shawonsarker84 6 분 전
Still number 4 volume leader 275M traded so far. GL
HMBL
ron_66271 ron_66271 6 분 전
Poor Answer. I Win.

Project West!

CRA.

Why BO?
He did his function as JD required.

JD isn’t going to be Treasure Secretary.

JD is highly conflicted and responsible for the Derivative Market Meltdown of 2008.
COOP
imho imho 8 분 전
"Investor
Hard to argue with those highlighted facts!"

Let me ask you a question. What does the term "both" refer to in Investors highlighted portion referenced below?

"The trial met both its co-primary and key secondary endpoints, showing statistically signific
AVXL
XMaster2023 XMaster2023 8 분 전
You mean, feel free to refute your conjecture. No thanks. I have made a living assessing people and their motives. I believe in LP. You on the other hand. It’s apparent you are a paid basher. Thanks for deleting my post. I keep records, and the lawyers will enjoy your tactics.
NWBO
weedtrader420 weedtrader420 12 분 전
BITCOIN XRP AIMAW Aqualung💦Cross eyed Mary $120,000 TARGET ✊😮‍💨☝️
BTCUSD
Saving Grace Saving Grace 14 분 전
Yes, when NDA's are removed, it's boom time. Everyone at the plant is excited and ready.

https://businessjournaldaily.com/wp-content/uploads/2024/10/Foxconn-Model-C-EV.jpg

https://i.vimeocdn.com/video/1780032285-1eadf9821975b71cc554aa3a7d443a4b59265d9b3a16081b2573d7c443
NRDE
ThoroughBread ThoroughBread 16 분 전
SFIO .0028 sleeper.
SFIO
glens0 glens0 17 분 전
CTOR last Aug. 6th the price was $49.00 now $1.32
CTOR
ThoroughBread ThoroughBread 19 분 전
SING @ .006 bounce-pop off this level. Daily volume increasing.
boi568 boi568 19 분 전
Yes, it's also true that guidelines allow for more discretion than rules. To a point.

If the governing science that applies to two applicants is the same, the FDA decisional criteria should be the same. In this case, if the AD stages in the trials are the same, the endpoints should be
AVXL
Hardazoak Hardazoak 20 분 전
Current Aabbg works fine, wallet works fine. New aabb wallet 2.0 with AI and moonpay exchange integrated coming. Stop with the lies gitreal, only you are believing your own lies.
AABB
KPIFF-LDDFF KPIFF-LDDFF 20 분 전
KPIFF
wadegarret wadegarret 21 분 전
Novice- AI stocks have mostly done their thing

I don't believe Stargate will add all that much to boost valuations further. I mean NVDA already sells for over a 30 something PE going forward, CRDO sells for an 85 PE going forward, CRWD sells for around an 80 PE going forward, PLTR
AES CRDO CRWD
PEACHMAN PEACHMAN 21 분 전
The exact opposite of what you say is true.LOLOLOLOL!!!!! I OWN you, kitty. Heart, mind, body and soul!! You fall into traps, you copy verbatim my posts. Have you ever had an independent thought in your life?

https://investorshub.advfn.com/uimage/uploads/2025/1/22/sdlmono_panther.pn
IFUS
pinhigh pinhigh 22 분 전
Well done video gimmee! RRX!
BIEL
Orange Cassidy Orange Cassidy 23 분 전
The Jared "whisperer" is still here in emoji form on every post. He has not gone anywhere. As it stands the mills are abandoned and this is still a sham. "Whats not to like?"
NBRI
bas2020 bas2020 23 분 전
Any shorting after approval will be total manipulation by the corrupt cabal... your bosses. Hopefully, we'll have MTD denial prior with a cease and desist order to go with it... to cut ya all off at the knees. 💥
NWBO
hssbwwmp hssbwwmp 24 분 전
Yes, I've seen them cite those factors in their reports as well as being flexible to adapt to them. So, it would seem that if AXXA was still able to grow revenue and reduce debt despite those factors, then the PPS should not have continued this long downtrend, correct? Something still is not comp
AXXA
RichieBoy RichieBoy 24 분 전
Minute 28 - Minute 40 is on AI

Keep in mind this is acutely political. So you'll be left wondering about this side of AI and oh that part of AI why aren't they important. They are important of course, but never before to date will you have seen such intense focus on this one facet.
AFFU
boarddork boarddork 26 분 전
That’s a lot of push pins and zig zag strings to make that ultimate conclusion.
COOP
weedtrader420 weedtrader420 26 분 전
BITCOIN XRP TRIUMPH MAGIC POWER $120,000 TARGET
BTCUSD
janice shell janice shell 27 분 전
She's one of the very few who actually deserves a pardon.
Hoskuld Hoskuld 28 분 전
This is not really true Boi - although I can imagine that logically it should be true. But, no 2 companies run their trials the same way. Usually. this is deliberate. The FDA cannot evaluate them the same way, as a result. The guidelines are NOT requirements. They are simply suggestions.
AVXL

최근 히스토리

Delayed Upgrade Clock